Silencing Antibiotic Resistance with Antisense Oligonucleotides

Area of Science:

• Molecular Biology
• Antimicrobial Resistance
• Drug Development

Background:

• Antisense technologies utilize oligonucleotides to inhibit gene expression, showing promise for various diseases.
• Current clinical applications of antisense drugs primarily target non-bacterial infections, with less progress in prokaryotic applications.
• A significant research focus is on developing antisense compounds to combat antibiotic resistance in bacterial pathogens.

Purpose of the Study:

• To review the development of antisense compounds designed to inhibit the expression of antibiotic resistance genes.
• To summarize strategies for using antisense technologies as adjuncts to existing antibiotics.

Main Methods:

• Utilizing various oligonucleotide analogs, including phosphorothioate, phosphorodiamidate morpholino, peptide nucleic acids, locked nucleic acids, and bridge nucleic acids.
• Employing mechanisms such as host RNase H or RNase P-mediated mRNA cleavage and steric hindrance for gene silencing.
• Targeting resistance mechanisms against diverse antibiotic classes like beta-lactams, carbapenems, aminoglycosides, chloramphenicol, macrolides, and fluoroquinolones.

Main Results:

• Demonstrated success in reducing resistance levels to various antibiotics through antisense compound application.
• Explored multiple oligonucleotide analog designs and delivery strategies for effective gene silencing in bacteria.
• Highlighted the potential of antisense compounds as adjuvants to restore antibiotic efficacy.

Conclusions:

• Antisense technologies represent a promising strategy to overcome antibiotic resistance.
• Further development is needed to fully realize the potential of antisense compounds in treating bacterial infections.
• These compounds can serve as valuable adjuncts to conventional antibiotics, enhancing their effectiveness.